Document is current
Any future updates will be listed below
-
Authors
Lombardo-del Toro, Paula
Bragado-Trigo, Irene
Arroyo, Pablo https://orcid.org/0000-0003-0632-4850
Tena-Cucala, Raquel
Bau, Laura
Matas, Elisabet
Muñoz-Vendrell, Albert https://orcid.org/0000-0001-8221-865X
Simó, Marta
Pons-Escoda, Albert https://orcid.org/0000-0003-4167-8291
Martínez-Yélamos, Antonio https://orcid.org/0000-0002-3725-0180
Martínez-Yélamos, Sergio https://orcid.org/0000-0001-9889-2040
Romero-Pinel, Lucía https://orcid.org/0000-0001-8054-0565
- License Information
-
More Information
Article History
Received: 17 March 2023
Revised: 4 July 2023
Accepted: 5 July 2023
First Online: 17 July 2023
Declarations
:
: Paula Lombardo-del Toro received funding for travel and congress attendance from Novartis and Lilly. Irene Bragado-Trigo, Pablo Arroyo, Raquel Tena-Cucala, Laura Bau, Elisabet Matas, Albert Muñoz-Vendrell, Antonio Martínez-Yélamos, Sergio Martínez-Yélamos and Lucía Romero-Pinel received honorarium for participating on advisory boards and for collaborations as consultants and for their work on scientific communications; they also received research support as well as funding for travel and congress-attending expenses from Roche, Biogen Idec, Novartis, TEVA, Merck, Genzyme, Sanofi, Bayer, Almirall, Horizon and Celgene. Marta Simó and Albert Pons-Escoda declare nothing to disclose.
: Ethics Committee approval was not necessary.
: Written informed consent was obtained from the patient and her relatives before publication.
